
    
      Treprostinil is approved as a continuous subcutaneous (SC) or intravenous (IV) infusion by
      the FDA for the treatment of WHO group I PAH with New York Heart Association (NYHA)
      Functional Class II, III or IV symptomatology. To date, treprostinil has not been studied in
      the setting of PoPH; however, it is commonly prescribed in this setting. This was an
      observational, open-label, multicenter study which documented the safety and efficacy profile
      of this agent in PoPH to facilitate orthotopic liver transplantation (OLT).
    
  